Table 2.
Laboratory marker comparison between the two Tocilizumab treated subgroups.
| TOCI on NIV/O2 (N = 16) | TOCI on ventilators (N = 26) | p value | |
|---|---|---|---|
| CRP, mg/L | 59.3 (21.6−112.7) | 114.6 (5.25−210) | 0.04 |
| IL-6, pg/mL | 58 (28.45−78.5) | 78.8 (46−161) | 0.06 |
| WBC, cell/μL | 4425 (3210−6115) | 6180 (5230−8130) | 0.009 |
| Neutrophil, cell/μL | 3130 (2310−4885) | 7235 (5430−9072) | 0.01 |
| Lymphocyte, cell/μL | 1020 (635−1165) | 650 (445−775) | 0.01 |
| NLR | 3.5 (2.5−5.1) | 8.2 (4.7−15.7) | 0.001 |
| LDH, IU/L | 494 (246.5−599) | 744 (580.75−1057) | 0.001 |
| CK, IU/L | 101 (78−179) | 197 (104.5−382.75) | 0.13 |
Legend: TOCI, tocilizumab treatment group; NIV, non-invasive ventilation; CRP, C-reactive protein; IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase; WBC, white, blood cell count; NLR, neutrophil to lymphocyte ratio. Data are presented as median (IQR).